Analysts Issue Forecasts for InflaRx FY2025 Earnings

InflaRx (NASDAQ:IFRX - Free Report) - Cantor Fitzgerald issued their FY2025 earnings per share estimates for InflaRx in a research report issued on Tuesday, April 29th. Cantor Fitzgerald analyst S. Seedhouse expects that the company will post earnings per share of ($0.87) for the year. Cantor Fitzgerald has a "Overweight" rating and a $10.00 price objective on the stock. The consensus estimate for InflaRx's current full-year earnings is ($1.04) per share.

InflaRx (NASDAQ:IFRX - Get Free Report) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.18. InflaRx had a negative return on equity of 65.98% and a negative net margin of 33,362.70%.

Several other brokerages have also recently issued reports on IFRX. HC Wainwright reiterated a "buy" rating and set a $8.00 price target on shares of InflaRx in a research report on Friday, March 21st. Guggenheim raised their price objective on shares of InflaRx from $7.00 to $10.00 and gave the company a "buy" rating in a research report on Wednesday, March 26th.

InflaRx Price Performance

Shares of InflaRx stock traded down $0.09 on Thursday, hitting $1.57. The company had a trading volume of 355,095 shares, compared to its average volume of 231,569. InflaRx has a 52 week low of $0.82 and a 52 week high of $2.82. The company has a market cap of $105.06 million, a PE ratio of -1.45 and a beta of 1.57. The business has a 50-day simple moving average of $1.21 and a 200-day simple moving average of $1.83.

Hedge Funds Weigh In On InflaRx

Several institutional investors and hedge funds have recently added to or reduced their stakes in IFRX. Cubist Systematic Strategies LLC purchased a new position in shares of InflaRx during the fourth quarter valued at $55,000. Northern Trust Corp increased its holdings in shares of InflaRx by 1,933.1% during the 4th quarter. Northern Trust Corp now owns 666,845 shares of the company's stock valued at $1,647,000 after acquiring an additional 634,045 shares during the last quarter. Two Sigma Securities LLC bought a new position in shares of InflaRx in the 4th quarter valued at approximately $28,000. Walleye Capital LLC bought a new stake in InflaRx during the fourth quarter worth approximately $51,000. Finally, Raymond James Financial Inc. acquired a new position in InflaRx during the fourth quarter valued at approximately $1,576,000. 42.39% of the stock is currently owned by hedge funds and other institutional investors.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.